BioPharmSignal logoBioPharmSignal

Biotech News

OraSure Technologies Appoints John D. Bertrand to its Board of Directors

OraSure Technologies, Inc. (OSUR)OraSure Technologies, Inc.FDA / regulatory

Enters into Cooperation Agreement with Altai Capital Board to Seek Shareholder Approval for Declassification at the 2026 Annual Meeting BETHLEHEM, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (“OraSure” and “OTI”) (NASDAQ: OSUR), a leader in point-of-need and home diagnostic

Related news

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-01-05 13:00 EST

OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review

DGXQuest Diagnostics2026-06-24 12:52 EST

Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing

INBSIntelligent Bio Solutions2026-01-28 13:30 EST

Intelligent Bio Solutions Initiates Additional Clinical Studies for FDA 510(k) Submission Supporting Planned Entry into Multi-Billion Dollar U.S. Market

INBSIntelligent Bio Solutions2026-06-02 12:30 EST

Intelligent Bio Solutions Commences Multi-Site Method Comparison Study for FDA 510(k) Submission

VRAXVirax Biolabs2025-08-26 11:30 EST

Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September

BJDXBluejay Diagnostics2025-11-10 12:30 EST

Bluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic Partnerships

VRAXVirax Biolabs2025-11-03 13:29 EST

Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes

SERASera Prognostics2026-06-30 20:05 EST

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS

BIAFbioAffinity Technologies, Inc.2026-03-10 11:47 EST

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic

View all latest news

OraSure Technologies, Inc.

Decentralized Diagnostics OraSure Technologies develops point-of-need and at-home diagnostic tests intended to make testing more accessible, private and convenient. Rapid-Test Portfolio The company's products cover infectious diseases and other conditions across consumer, clinical, public-health and community settings. Subsidiaries...

Recent company news

OSUROraSure Technologies, Inc.2026-08-05 20:05 EST

OraSure Announces Second Quarter 2026 Financial Results

OSUROraSure Technologies, Inc.2026-07-22 20:10 EST

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OSUROraSure Technologies, Inc.2026-07-21 20:30 EST

OraSure Receives Emergency Use Authorization for Second Generation Ebola Test

OSUROraSure Technologies, Inc.2026-06-11 12:00 EST

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OSUROraSure Technologies, Inc.2026-05-06 20:05 EST

OraSure Announces First Quarter 2026 Financial Results

Stock data

Close
4.00 USD
Market cap
275.39M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States